H Lundbeck A/S
CSE:HLUN A

Watchlist Manager
H Lundbeck A/S Logo
H Lundbeck A/S
CSE:HLUN A
Watchlist
Price: 32.85 DKK -0.3%
Market Cap: 32.7B DKK
Have any thoughts about
H Lundbeck A/S?
Write Note

H Lundbeck A/S
Pre-Tax Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

H Lundbeck A/S
Pre-Tax Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Pre-Tax Income CAGR 3Y CAGR 5Y CAGR 10Y
H Lundbeck A/S
CSE:HLUN A
Pre-Tax Income
kr3B
CAGR 3-Years
16%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Novo Nordisk A/S
CSE:NOVO B
Pre-Tax Income
kr119.3B
CAGR 3-Years
27%
CAGR 5-Years
20%
CAGR 10-Years
14%
ALK-Abello A/S
CSE:ALK B
Pre-Tax Income
kr647m
CAGR 3-Years
86%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
S
Stenocare A/S
CSE:STENO
Pre-Tax Income
-kr18.8m
CAGR 3-Years
-11%
CAGR 5-Years
-39%
CAGR 10-Years
N/A
No Stocks Found

H Lundbeck A/S
Glance View

Market Cap
32.6B DKK
Industry
Pharmaceuticals

Founded in 1915 by Hans Lundbeck, H. Lundbeck A/S has grown from a small trading company into a notable player within the pharmaceutical industry, specializing in the treatment of brain diseases. Over the decades, the company honed its focus on neuroscience, particularly targeting mental health disorders. This specialization has allowed Lundbeck to establish a strong presence in the therapeutic areas of depression, schizophrenia, Alzheimer's, and Parkinson's diseases. The company's operations are grounded in a rigorous commitment to research and development, constantly seeking breakthroughs that can transform mental health treatment. A significant portion of its revenue is channeled back into R&D to maintain its pipeline of innovative pharmaceuticals, ensuring a future driven by new drug discoveries that align with patient needs. Lundbeck’s revenue streams primarily stem from its portfolio of prescription medicines, marketed globally across numerous countries. The company capitalizes particularly on a few blockbuster drugs, forming strategic alliances and partnerships to expand its reach and efficacy. Through a robust distribution network, Lundbeck effectively channels its products from manufacturing through to consumers, including hospitals and pharmacies. Moreover, the company benefits from strategic collaborations with other pharmaceutical giants, enhancing its footprint in competitive markets. By continually investing in cutting-edge research and leveraging strategic partnerships, Lundbeck maintains its mission of delivering effective central nervous system therapies, ensuring a sustainable growth trajectory.

HLUN A Intrinsic Value
65.73 DKK
Undervaluation 50%
Intrinsic Value
Price

See Also

What is H Lundbeck A/S's Pre-Tax Income?
Pre-Tax Income
3B DKK

Based on the financial report for Dec 31, 2023, H Lundbeck A/S's Pre-Tax Income amounts to 3B DKK.

What is H Lundbeck A/S's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 3Y
16%

Over the last year, the Pre-Tax Income growth was 21%. The average annual Pre-Tax Income growth rates for H Lundbeck A/S have been 16% over the past three years .

Back to Top